Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02).

Abstract

2004 Background: Glioblastomas (GBM) frequently have EGFR amplification/mutations and inactivation of PTEN. Although single agent EGFR and mTOR inhibitors have limited activity, combinations of these agents may be more effective. METHODS The North American Brain Tumor Consortium conducted a phase I/II study of the EGFR inhibitor erlotinib in combination… (More)

Topics

Cite this paper

@article{Chang2009PhaseIS, title={Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02).}, author={S. M. Chang and Jana Christine Kuhn and Kathleen R. Lamborn and Tim F. Cloughesy and I A Robins and Frank Lieberman and Alfred Wei Tak Yung and Janet E. Dancey and Maria D Prados and Pingzi Wen}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2009}, volume={27 15_suppl}, pages={2004} }